Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020722562> ?p ?o ?g. }
- W2020722562 endingPage "3813" @default.
- W2020722562 startingPage "3804" @default.
- W2020722562 abstract "Increasing the aglycone lipophilicity of a series of polysulfated oligosaccharide glycoside heparan sulfate (HS) mimetics via attachment of a steroid or long chain alkyl group resulted in compounds with significantly improved in vitro and ex vivo antiangiogenic activity. The compounds potently inhibited heparanase and HS-binding angiogenic growth factors and displayed improved antitumor and antimetastatic activity in vivo compared with the earlier series. Preliminary pharmacokinetic analyses also revealed significant increases in half-life following iv dosing, ultimately supporting less frequent dosing regimens in preclinical tumor models compared with other HS mimetics. The compounds also displayed only mild anticoagulant activity, a common side effect usually associated with HS mimetics. These efforts led to the identification of 3β-cholestanyl 2,3,4,6-tetra-O-sulfo-α-d-glucopyranosyl-(1→4)-2,3,6-tri-O-sulfo-α-d-glucopyranosyl-(1→4)-2,3,6-tri-O-sulfo-α-d-glucopyranosyl-(1→4)-2,3,6-tri-O-sulfo-β-d-glucopyranoside, tridecasodium salt (PG545, 18) as a clinical candidate. Compound 18 was recently evaluated in a phase I clinical trial in cancer patients." @default.
- W2020722562 created "2016-06-24" @default.
- W2020722562 creator A5002868385 @default.
- W2020722562 creator A5003810137 @default.
- W2020722562 creator A5013562277 @default.
- W2020722562 creator A5036215310 @default.
- W2020722562 creator A5046327179 @default.
- W2020722562 creator A5059115631 @default.
- W2020722562 creator A5061208744 @default.
- W2020722562 creator A5063473170 @default.
- W2020722562 creator A5069308257 @default.
- W2020722562 creator A5073389700 @default.
- W2020722562 creator A5074142514 @default.
- W2020722562 creator A5083639088 @default.
- W2020722562 creator A5083803543 @default.
- W2020722562 creator A5091806980 @default.
- W2020722562 date "2012-04-13" @default.
- W2020722562 modified "2023-10-01" @default.
- W2020722562 title "Discovery of PG545: A Highly Potent and Simultaneous Inhibitor of Angiogenesis, Tumor Growth, and Metastasis" @default.
- W2020722562 cites W1963805168 @default.
- W2020722562 cites W1967600348 @default.
- W2020722562 cites W1968652549 @default.
- W2020722562 cites W1970849520 @default.
- W2020722562 cites W1973733841 @default.
- W2020722562 cites W1977999028 @default.
- W2020722562 cites W1980077962 @default.
- W2020722562 cites W1981160446 @default.
- W2020722562 cites W1982423863 @default.
- W2020722562 cites W1986012385 @default.
- W2020722562 cites W1991286340 @default.
- W2020722562 cites W2004105893 @default.
- W2020722562 cites W2006570056 @default.
- W2020722562 cites W2010117209 @default.
- W2020722562 cites W2016569548 @default.
- W2020722562 cites W2017322644 @default.
- W2020722562 cites W2019428611 @default.
- W2020722562 cites W2020113016 @default.
- W2020722562 cites W2021036829 @default.
- W2020722562 cites W2021130116 @default.
- W2020722562 cites W2036469214 @default.
- W2020722562 cites W2054578983 @default.
- W2020722562 cites W2062680870 @default.
- W2020722562 cites W2070251374 @default.
- W2020722562 cites W2074631079 @default.
- W2020722562 cites W2084740377 @default.
- W2020722562 cites W2100307602 @default.
- W2020722562 cites W2120895512 @default.
- W2020722562 cites W2140088548 @default.
- W2020722562 cites W2145662716 @default.
- W2020722562 cites W2147146770 @default.
- W2020722562 cites W2152547358 @default.
- W2020722562 cites W2155494269 @default.
- W2020722562 cites W2170499574 @default.
- W2020722562 cites W2793323124 @default.
- W2020722562 doi "https://doi.org/10.1021/jm201708h" @default.
- W2020722562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22458531" @default.
- W2020722562 hasPublicationYear "2012" @default.
- W2020722562 type Work @default.
- W2020722562 sameAs 2020722562 @default.
- W2020722562 citedByCount "105" @default.
- W2020722562 countsByYear W20207225622012 @default.
- W2020722562 countsByYear W20207225622013 @default.
- W2020722562 countsByYear W20207225622014 @default.
- W2020722562 countsByYear W20207225622015 @default.
- W2020722562 countsByYear W20207225622016 @default.
- W2020722562 countsByYear W20207225622017 @default.
- W2020722562 countsByYear W20207225622018 @default.
- W2020722562 countsByYear W20207225622019 @default.
- W2020722562 countsByYear W20207225622020 @default.
- W2020722562 countsByYear W20207225622021 @default.
- W2020722562 countsByYear W20207225622022 @default.
- W2020722562 countsByYear W20207225622023 @default.
- W2020722562 crossrefType "journal-article" @default.
- W2020722562 hasAuthorship W2020722562A5002868385 @default.
- W2020722562 hasAuthorship W2020722562A5003810137 @default.
- W2020722562 hasAuthorship W2020722562A5013562277 @default.
- W2020722562 hasAuthorship W2020722562A5036215310 @default.
- W2020722562 hasAuthorship W2020722562A5046327179 @default.
- W2020722562 hasAuthorship W2020722562A5059115631 @default.
- W2020722562 hasAuthorship W2020722562A5061208744 @default.
- W2020722562 hasAuthorship W2020722562A5063473170 @default.
- W2020722562 hasAuthorship W2020722562A5069308257 @default.
- W2020722562 hasAuthorship W2020722562A5073389700 @default.
- W2020722562 hasAuthorship W2020722562A5074142514 @default.
- W2020722562 hasAuthorship W2020722562A5083639088 @default.
- W2020722562 hasAuthorship W2020722562A5083803543 @default.
- W2020722562 hasAuthorship W2020722562A5091806980 @default.
- W2020722562 hasConcept C112705442 @default.
- W2020722562 hasConcept C121608353 @default.
- W2020722562 hasConcept C126322002 @default.
- W2020722562 hasConcept C150903083 @default.
- W2020722562 hasConcept C155138218 @default.
- W2020722562 hasConcept C185592680 @default.
- W2020722562 hasConcept C194671627 @default.
- W2020722562 hasConcept C201399114 @default.
- W2020722562 hasConcept C202751555 @default.
- W2020722562 hasConcept C207001950 @default.
- W2020722562 hasConcept C26291073 @default.